Clinical Relevance of the Reverse Lipopolysaccharide Transport Pathway in Patients With Acute Peritonitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

27 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-19

Study Completion Date

2022-10-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

When there is infection in the intra-abdominal area, bacteria secrete toxins that are absorbed by the peritoneum. These toxins then bind to lipoproteins (which carry cholesterol in the blood) and are eliminated by the liver. Phospholipid transfer protein (PLTP) is a protein that facilitates the binding of bacterial toxins to lipoproteins and thus their elimination.

The objective of this study is to study the relationship between PLTP and the elimination of bacterial toxins in humans. A better understanding of the elimination of these toxins will lead to a better understanding of the disease. The ultimate objective is to improve the management of intra-abdominal infections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Peritoneal Immune Response in Patients With Severe Intra-abdominal Sepsis Managed With Laparostomy and Vacuum Assisted Closure (VAC)

NCT01410526

Abdominal Sepsis

COMPLETED

Comparative Study of the Protein C Pathway in Septic and Non Septic Patients With Organ Failure

NCT00361725

Severe Sepsis Organ Failure

TERMINATED

Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock

NCT01222663

Peritonitis Septic Shock

COMPLETED PHASE3

Comparison of Short Peptide and Whole Protein Formula in the Early Enteral Nutrition of Patients With Sepsis

NCT07038057

Sepsis Nutrition

NOT_YET_RECRUITING NA

Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis

NCT04576819

Sepsis Shock, Septic

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peritonitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with suspected peritonitis

Secondary peritonitis, sepsis and endotoxemia

blood samples

Intervention Type BIOLOGICAL

4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood samples

4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* person who has given oral consent (patient or family member)
* pre-operative SEPSIS criteria (qSOFA \>=2) or vasopressor or mechanical ventilation treatment
* admitted to the operating room for suspected generalized secondary peritonitis

Exclusion Criteria

* person not affiliated to national health insurance
* person under legal protection (curatorship, guardianship)
* person under court order
* pregnant, parturient or breastfeeding woman
* minor
* immunosuppression (HIV infection, corticosteroid treatment \> 0.15 mg/kg/day prednisolone equivalent \> 2 weeks, immunosuppressive treatment, primary cellular immune deficiency)
* decision to limit or stop therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No